Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | CLK3 | P49761 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759015 | 0.83 | TAAR1 (0.54) | NTRK1MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL2864778 | 0.80 | ITK (0.54) | NTRK1MAP2K4LRRK2 | |
| SCHEMBL2861096 | 0.79 | MAP2K4 (0.51) | NTRK1MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL6545253 | 0.78 | MAP2K4 (0.52) | NTRK1MAP2K4 | |
| SCHEMBL14516332 | 0.75 | AURKA (0.59) | NTRK1MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL2860957 | 0.74 | AURKA (0.66) | MAP2K4LRRK2MAPK1 | |
| SCHEMBL2868118 | 0.74 | MAP2K4 (0.48) | NTRK1MAP2K4LRRK2CLK2CLK3 | |
| SCHEMBL4153296 | 0.72 | CLK2 (0.52) | NTRK1MAP2K4LRRK2CLK2CLK3 | |
| SCHEMBL6545822 | 0.72 | MAP2K4 (0.44) | NTRK1MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL2872497 | 0.72 | DYRK1A (0.52) | NTRK1MAP2K4CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| CN-1300116-C | 1H-indazole compounds | EISAI CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1512987-A | Novel 1H-indazole compound | ������������ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NTRK1 1241/4885MAP2K4 61/4885LRRK2 282/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | NTRK1 1387/4885MAP2K4 53/4885LRRK2 817/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NTRK1 1241/4885MAP2K4 61/4885LRRK2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.